ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Activity

79 hedge funds and large institutions have $1.03B invested in Adaptimmune Therapeutics in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 20 closing their positions.

Holders
79
Holders Change
+2
Holders Change %
+2.6%
% of All Funds
1.6%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
23
Increased
23
Reduced
19
Closed
20
Calls
$2.02M
Puts
$1.04M
Net Calls
+$985K
Net Calls Change
+$6.21M

Top Buyers

1
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$56.5M
2
Citadel Advisors
2
Citadel Advisors
Florida
$39M
3
Victory Capital Management
3
Victory Capital Management
Texas
$23.3M
4
ACA
4
Avoro Capital Advisors
New York
$87.8M
5
PHS
5
PFM Health Sciences
California
$6.78M

Top Sellers

1
RCM
1
RA Capital Management
Massachusetts
$90.4M
2
ACP
2
Acuta Capital Partners
California
$0
3
VA
3
VR Adviser
New York
$0
4
Marshall Wace
4
Marshall Wace
United Kingdom
$0
5
JGC
5
J. Goldman & Co
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
HT
101
HAP Trading
New York
– – – –
CHA
102
Carmichael Hill & Associates
Maryland
$0 40 +40 New
PCS
103
Personal CFO Solutions
New Jersey
$0 25,797 +25,797 New
1 2 3 4
5